Landos Biopharma, Inc.
LABP · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | 0.84 | -0.19 | -0.14 |
| FCF Yield | -89.15% | -227.44% | -14.23% | -4.81% |
| EV / EBITDA | 0.64 | 0.41 | -4.76 | -15.92 |
| Quality | ||||
| ROIC | -71.49% | -100.26% | -50.63% | -158.96% |
| Gross Margin | 0.00% | 0.00% | 98.91% | 0.00% |
| Cash Conversion Ratio | 0.93 | 1.17 | 0.70 | 0.76 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | – | – | – |
| Free Cash Flow Growth | 55.27% | -66.46% | -18.83% | -130.69% |
| Safety | ||||
| Net Debt / EBITDA | 1.65 | 0.90 | 0.21 | 0.08 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.10 |
| Cash Conversion Cycle | 0.00 | -2,172.92 | -24,037.86 | -19,203.80 |